

---

## ESOCAP ANNOUNCES ISSUE OF A PATENT IN MEXICO FOR ITS SMART APPLICATION TECHNOLOGY IN THE UPPER GASTROINTESTINAL TRACT



*Basel, Switzerland, December 3, 2021*

EsoCap AG announced today that the Mexican Patent and Trademark Office has issued a patent under number 383626, based on Patent Application No. MX/a/2017/007566.

The patent is directed at the smart application technology enabling effective topical treatment of several diseases of the esophagus. The patent is already granted in key countries, such as the USA and Japan.

EsoCap AG is pursuing similar patent applications in other regions and countries, including Europe, as well as further strategic countries. "Issue of the Mexican patent confirms the extremely innovative nature of EsoCap's technology," commented Isabelle Racamier, EsoCap AG CEO.

"Ensuring a robust intellectual property position around EsoCap technology is crucial to advancing our development program and the claims granted are an acknowledgement of the innovative nature of our technology." EsoCap has developed a unique, proprietary drug delivery platform allowing the efficient topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract.

"EsoCap smart application technology represents a paradigm shift for the effective and safe treatment of esophageal diseases," said Dr Peter Stangier, Director Strategic Planning at EsoCap AG. "Our technology offers maximum flexibility, as multiple relevant drug substances, including biologics and further innovative compounds, can be incorporated into the thin film, making the smart drug delivery platform applicable to various clinical indications."

### About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve with the current standard of care, due to the ultra-short drug contact time of one to two seconds from the mouth to the stomach. Lead candidate ESO-101 has received Orphan Drug Designation from the U.S. Food & Drug Administration (FDA) for the treatment of EoE and is in clinical development for this indication.

EsoCap technology will be beneficial in at least six therapeutic indications affecting 370 million patients.

For more information, please visit [www.esocapbiotech.com](http://www.esocapbiotech.com) and follow EsoCap on [LinkedIn](#) and [Twitter](#).

### Contact:

Isabelle Racamier, CEO  
EsoCap AG  
Malzgasse 9  
4052 Basel  
Switzerland

[isabelle.racamier@esocapbiotech.com](mailto:isabelle.racamier@esocapbiotech.com)